SecBot

SecBot
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001649989

OTLK

Outlook Therapeutics, Inc.
$0.5778 ▲ +0.49%
Prev close $0.5750
Market cap$108.0M
ConsensusBuy
12-mo target$5.03 (+765.8%)
▲ Bullish
Analyst conviction 7/10
Insider Buying Cluster (2 insiders)High Impact Filing (7/10)18 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on OTLK right now — valuation, ownership and activity at a glance.
Market Cap
$108.0M
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (70%)
Inst. Holders
49 funds
Inst. Value
$26.3M
Inst. Activity
18 buys / 2 sells
Insider Activity
$7.9M buy / $0.00 sell
Insider Net $
$7.9M
Social Sentiment
66° Warm
SEC Reports
20
Press Releases
8
Price chart 30d -7.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Application represents an important step in supporting reimbursement
Sep 1, 2026 Insider
Lundquist Kevin Michael was granted 500,000 shares
Chief Financial Officer
Aug 14, 2026 SEC
Outlook Therapeutics reported Q3 FY2026 results with net loss of $20.3M ($0.15 GAAP EPS, $0.09 adjusted) and revenue of
8-K — Impact 6/10
Aug 14, 2026 SEC
Outlook Therapeutics priced a $55.0M registered direct offering of 55,555,556 shares of common stock and accompanying wa
8-K — Impact 6/10
Aug 14, 2026 SEC
Outlook Therapeutics priced a $55M underwritten public offering of 55.6M shares and 55.6M warrants at $0.99/unit, repres
424B5 — Impact 7/10
Aug 14, 2026 Insider
KENYON LAWRENCE A bought 101,010 shares
Chief Financial Officer
Aug 14, 2026 Insider
KENYON LAWRENCE A bought 101,010 shares
Chief Financial Officer
Aug 13, 2026 Press
Outlook Therapeutics priced a dilutive underwritten public offering of 55.6M shares and warrants at $0.99/unit, raising
Impact 7/10
Analyst ratings buy % +9.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Buy 70% rate it Buy or better · 10 analysts
Strong Buy 2 20% Buy 5 50% Hold 3 30% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 11, 2026Ascendiant CapitalMAINTAINBuy 40%
Aug 14, 2026BTIGREITERATEBuy 53%
Jul 27, 2026HC Wainwright & Co.MAINTAINNeutral 43%
Jul 27, 2026BTIGUPGRADEBuy 53%
Jun 11, 2026Ascendiant CapitalMAINTAINBuy 40%
May 18, 2026BTIGDOWNGRADENeutral 53%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 20262530070%
Aug 1, 20262530070%
Jul 1, 20262530070%
Jun 1, 20262520078%
May 1, 20262520078%
Apr 1, 20262520078%
Mar 1, 20262530070%
Feb 1, 20262530070%
Price targets
Where 4 covering analysts think OTLK trades over the next 12 months.
$5.03 +765.8% upside Strong Buy
Current$0.5804 Low$1.60 Median$4.00 High$10.50 4 analysts
$1.60$10.50
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
66°
Warm
BearishNeutralBullish
25 mentions 12 bullish 3 bearish 10 neutral
Recent posts
pennystocks Bullish 2mo ago
What is up with OTLK? Is this a sell the news situation?
▲ 1 · 💬 4· ⚡ 0.5
stocks Neutral 2mo ago
$OTLK ON THE MOVE
▲ 1 · 💬 1· ⚡ 0.5
pennystocks Bearish 2mo ago
OTLK - FDA Decision
▲ 1 · 💬 1· ⚡ 0.5
pennystocks Bullish 3mo ago
5 of the 6 biotech names I posted 5 weeks ago hit their catalyst (and the 1 that hasn't)
▲ 1 · 💬 1· ⚡ 0.5
stocks Neutral 3mo ago
i bought Outlook theraputix (OTLK) at $1.66/ share
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 6 bullish, 9 bearish, 2 mixed, 3 neutral · avg impact 6.1/10.Plus 8 press releases.
BEARISH8-K6/10
Outlook Therapeutics reported Q3 FY2026 results with net loss of $20.3M ($0.15 GAAP EPS, $0.09 adjus
Aug 14, 2026
BEARISH8-K6/10
Outlook Therapeutics priced a $55.0M registered direct offering of 55,555,556 shares of common stock
Aug 14, 2026
BEARISH424B57/10
Outlook Therapeutics priced a $55M underwritten public offering of 55.6M shares and 55.6M warrants a
Aug 14, 2026
MIXEDPRESS-RELEASE7/10
Outlook Therapeutics reported a GAAP net loss of $0.15 per share for Q3 FY2026, significantly missin
Aug 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Application represents an important step in supporting reimbursement
Sep 30, 2026
short_volume
Short Volume: OTLK — 62.2% short (3.3M / 5.3M)
Short: 3,267,008 | Exempt: 12,392 | TRF Vol: 5,254,206 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: OTLK — 61.9% short (1.8M / 2.9M)
Short: 1,804,832 | Exempt: 2 | TRF Vol: 2,916,231 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: OTLK — 60.7% short (1.1M / 1.7M)
Short: 1,060,922 | Exempt: 5,588 | TRF Vol: 1,748,136 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: OTLK — 57.1% short (1.0M / 1.8M)
Short: 1,039,168 | Exempt: 150 | TRF Vol: 1,819,781 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.07$-0.08–$-0.0774.1%-36.4%2↑ 0↓$0.0B2
Next Q$-0.05$-0.08–$-0.0178.8%+6.7%1↑ 0↓$0.0B3
Current FY$-0.43$-0.45–$-0.4277.0%+11.8%—$0.0B2
Next FY$-0.12$-0.27–$-0.0372.4%+25.0%1↑ 0↓$0.0B3
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.075—
7d ago$-0.060-0.015
30d ago$-0.055-0.020
60d ago$-0.080+0.005
90d ago$-0.080+0.005
Institutional ownership
Which big funds own OTLK (from quarterly 13F filings) and who is adding or trimming.
49 institutional holders with $26.3M total value (17,293,275 shares) as of 2026-Q2. Top holders: ROYAL, VANGUARD, MARSHALL. Net buying activity: 18 institutions added/increased vs 2 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
ROYAL BANK OF CANADA156$0.000.0%ADD +83.5%
VANGUARD CAPITAL MANAGEMENT LLC4,376,872$7.0M26.5%DOUBLED +122.5%
MARSHALL WACE, LLP1,987,578$3.2M12.0%—
BlackRock, Inc.1,668,579$2.7M10.1%DOUBLED +249.5%
JANE STREET GROUP, LLC1,425,270$2.3M8.6%DOUBLED +305.3%
GEODE CAPITAL MANAGEMENT, LLC1,245,868$2.0M7.5%DOUBLED +106.4%
SUSQUEHANNA INTERNATIONAL GROUP, LLP968,190$1.5M5.9%DOUBLED +622.1%
VANGUARD FIDUCIARY TRUST CO661,664$1.1M4.0%DOUBLED +274.8%
SUSQUEHANNA INTERNATIONAL GROUP, LLP542,200$862.1K3.3%DOUBLED +622.1%
STATE STREET CORP539,802$858.3K3.3%DOUBLED +231.0%
Recent position changes
FundActionPrevCurrentChangeValue
ROYAL BANK OF CANADAADD85156+83.5%—
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED1,967,1604,376,872+122.5%$7.0M
BlackRock, Inc.DOUBLED477,4711,668,579+249.5%$2.7M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED603,6061,245,868+106.4%$2.0M
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED134,084968,190+622.1%$1.5M
VANGUARD FIDUCIARY TRUST CODOUBLED176,529661,664+274.8%$1.1M
STATE STREET CORPDOUBLED163,102539,802+231.0%$858.3K
RAYMOND JAMES FINANCIAL INCDOUBLED27,051332,051+1127.5%$528.0K
GROUP ONE TRADING LLCDOUBLED113,701246,428+116.7%$391.8K
NORTHERN TRUST CORPDOUBLED67,390237,561+252.5%$377.7K
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 20 transactions. Net $7.9M — $7.9M bought, $0.00 sold.
DateInsiderTitleTypeSharesPriceValue
Sep 1, 2026Lundquist Kevin MichaelChief Financial OfficerAWARD500,000——
Aug 14, 2026KENYON LAWRENCE AChief Financial OfficerBUY101,010——
Aug 14, 2026KENYON LAWRENCE AChief Financial OfficerBUY101,010——
Aug 14, 2026Jahr Robert CharlesChief Executive OfficerBUY151,515——
Aug 14, 2026Jahr Robert CharlesChief Executive OfficerBUY151,515——
Aug 12, 2026Sukhtian Ghiath M.DirectorBUY2,525,252$0.9900$2.5M
Aug 12, 2026Sukhtian Ghiath M.DirectorBUY2,525,252——
Jul 29, 2026Sukhtian Faisal GhiathDirectorBUY95,398$1.05$100.0K
Jul 21, 2026KENYON LAWRENCE AChief Financial OfficerAWARD210,078——
Jul 21, 2026Jahr Robert CharlesChief Executive OfficerAWARD100,000——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for OTLK.
Shares short
32,220,502
Settlement Sep 15, 2026
Change vs prior
-2.1%
Semi-monthly cycle
Days to cover
7.7
At avg daily volume
Of shares outstanding
≈13.2%
Estimate — not % of float
HaltedCodeReasonStatus
Jul 24, 2026LUDPVolatility PauseResumed
Jul 24, 2026T1News PendingNot resumed
Jul 24, 2026T2News ReleasedNot resumed
Jul 24, 2026T3Resumption ScheduledResumed
All OTLK filing & press-release reports (34)